Enter your keywords

Budesonide orodispersible tablets for maintenance of remission in eosinophilic oesophagitis

Budesonide orodispersible tablets (Jorveza) are indicated for induction and maintenance of remission in adults with eosinophilic oesophagitis. A NICE technology appraisal recommended budesonide ODT for induction of remission but did not address maintenance. This review assesses the evidence for use in maintenance treatment. Download the full review below to read more.

Gastro-intestinal System

This report looks at prescribing trends in primary care for for the Gastro-intestinal system at CCG and STP level with particular focus on Dyspepsia, Antisecretory drugs, Acute Diarrhoea, Chronic Bowel Disorders and Laxatives. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Bi-annually Data Period April 2018 […]

Long-Term Use Of PPIs – Bulletin

Long-term use of PPIs is not recommended in several indications as it has been linked to adverse effects including hypomagnesaemia, vitamin B12 deficiency, increased fracture risk and increased risk of MI. This bulletin aims to highlight the current national guidance, potential adverse effects associated with long term PPI use and prescribing patterns on a CCG […]

Naldemedine for the treatment of opioid induced constipation

Naldemedine is the second oral peripherally acting μ-opioid receptor antagonist to be launched,after naloxegol. It is licensed for the treatment of opioid induced constipation (OIC) in adults whohave previously been treated with laxatives.